tiprankstipranks
Advertisement
Advertisement

TVRD Stock Latest News

Tvardi, Biogen, FuelCell, Magnite, Canadian Tire Trending
Weekend UpdatesTvardi, Biogen, FuelCell, Magnite, Canadian Tire Trending
9d ago
BIIB
FCEL
Tvardi Therapeutics Shareholders Approve Directors and Governance Measures
PremiumCompany Announcements
Tvardi Therapeutics Shareholders Approve Directors and Governance Measures
10d ago
8K
TVRD
Tvardi Therapeutics initiated with a Buy at H.C. Wainwright
PremiumThe Fly
Tvardi Therapeutics initiated with a Buy at H.C. Wainwright
14d ago
TVRD
5 Healthcare Stocks Set to Join the Russell 3000
PremiumMarket News
5 Healthcare Stocks Set to Join the Russell 3000
27d ago
QSI
AGEN
Tvardi Therapeutics reports Q1 EPS (73c), consensus (72c)
PremiumThe Fly
Tvardi Therapeutics reports Q1 EPS (73c), consensus (72c)
1M ago
TVRD
Tvardi Therapeutics files $200M mixed securities shelf
PremiumThe FlyTvardi Therapeutics files $200M mixed securities shelf
2M ago
TVRD
Tvardi Therapeutics downgraded to Underweight from Equal Weight at Barclays
Premium
The Fly
Tvardi Therapeutics downgraded to Underweight from Equal Weight at Barclays
2M ago
TVRD
Buy Rating on Tvardi: Differentiated STAT3 Platform, Upcoming TTI-109/TTI-101 Catalysts, and Attractive Risk‑Reward Through 2026
Premium
Ratings
Buy Rating on Tvardi: Differentiated STAT3 Platform, Upcoming TTI-109/TTI-101 Catalysts, and Attractive Risk‑Reward Through 2026
3M ago
TVRD
Tvardi Therapeutics Warns Animal Welfare Rules Could Raise Costs and Delay Drug Development
PremiumCompany Announcements
Tvardi Therapeutics Warns Animal Welfare Rules Could Raise Costs and Delay Drug Development
3M ago
TVRD
Tvardi Therapeutics price target lowered to $3 from $4 at Piper Sandler
PremiumThe Fly
Tvardi Therapeutics price target lowered to $3 from $4 at Piper Sandler
3M ago
TVRD
Tvardi Therapeutics price target lowered to $4 from $5 at Barclays
PremiumThe Fly
Tvardi Therapeutics price target lowered to $4 from $5 at Barclays
3M ago
TVRD
Tvardi Therapeutics reports Q4 EPS (78c), consensus (57c)
PremiumThe Fly
Tvardi Therapeutics reports Q4 EPS (78c), consensus (57c)
3M ago
TVRD
Tvardi Therapeutics Sets Key Deadlines for 2026 Meeting
PremiumCompany AnnouncementsTvardi Therapeutics Sets Key Deadlines for 2026 Meeting
4M ago
8K
TVRD
Tvardi Therapeutics: Positive Phase 2 IPF Signal and Next-Gen STAT3 Pipeline Position Shares as a Buy Ahead of 2026 Catalysts
Premium
Ratings
Tvardi Therapeutics: Positive Phase 2 IPF Signal and Next-Gen STAT3 Pipeline Position Shares as a Buy Ahead of 2026 Catalysts
4M ago
TVRD
Tvardi Therapeutics upgraded to Buy from Neutral at Lucid Capital
Premium
The Fly
Tvardi Therapeutics upgraded to Buy from Neutral at Lucid Capital
5M ago
TVRD
Tvardi Therapeutics updates STAT3 fibrosis-focused clinical pipeline
PremiumCompany Announcements
Tvardi Therapeutics updates STAT3 fibrosis-focused clinical pipeline
5M ago
8K
TVRD
Tvardi Therapeutics announces further Phase 2 REVERT IPF data
PremiumThe Fly
Tvardi Therapeutics announces further Phase 2 REVERT IPF data
5M ago
TVRD
Tvardi Therapeutics: Buy Rating Reaffirmed Amid Upcoming Catalysts and Risk-Reward Scenario
PremiumRatings
Tvardi Therapeutics: Buy Rating Reaffirmed Amid Upcoming Catalysts and Risk-Reward Scenario
7M ago
TVRD
Tvardi Therapeutics Advances STAT3 Inhibitor Clinical Trials
PremiumCompany Announcements
Tvardi Therapeutics Advances STAT3 Inhibitor Clinical Trials
7M ago
8K
TVRD
Tvardi Therapeutics Faces Financial Hurdles Amidst Ongoing Product Development Challenges
PremiumCompany AnnouncementsTvardi Therapeutics Faces Financial Hurdles Amidst Ongoing Product Development Challenges
7M ago
TVRD
Promising Pipeline and Financial Stability Drive Buy Rating for Tvardi Therapeutics
Premium
Ratings
Promising Pipeline and Financial Stability Drive Buy Rating for Tvardi Therapeutics
7M ago
TVRD
Tvardi Therapeutics reports Q3 EPS (59c), consensus (96c)
Premium
The Fly
Tvardi Therapeutics reports Q3 EPS (59c), consensus (96c)
7M ago
TVRD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >